WHWilliam P. Horan

William P. Horan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


William P. Horan has a total of 140 co-authors. Here are the top co-authors by number of shared publications:

  • Michael F. Green

    VA Greater Los Angeles Healthcare System

    23 shared publications
  • Jonathan K. Wynn

    Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA

    18 shared publications
  • Junghee Lee

    Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, United States of America

    10 shared publications
  • Robert S. Kern

    VA Greater Los Angeles Healthcare System

    8 shared publications
  • Keith H. Nuechterlein

    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA

    7 shared publications
  • Joseph Ventura

    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA

    5 shared publications

Latest Publications

  • Open Access

    A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 2: Perceived Changes in Subjective Quality of Life and Medication Satisfaction

    by Peter Weiden, Cory Saucier, April M Foster, Amy Claxton, Soumya Chatuvedi, Colin Sauder, Kaitlin LaGasse, Sloan Rucker, Kristi Jackson, Stephen R Marder, et al.

    Introduction: The FDA approval in 2024 of the M1/M4 muscarinic receptor agonist xanomeline and trospium chloride (formerly known as KarXT) introduces a novel alternative to dopamine-receptor antagonism or partial agonism for schizophrenia treatment. All prior approved treatments rely on direct D2-receptor antagonism or partial agonism, limiting patient experiences to this mechanism. To explore this shift, we conducted a qualitative study examining patient experiences with a muscarinic receptor agonist. A companion report addresses perceived symptom changes; this report focuses on changes in quality of life (QoL) and medication satisfaction. Study Methods: A qualitative substudy was embedded in a larger 52-week open-label trial of xanomeline/trospium monotherapy in stable schizophrenia outpatients transitioned from standard antipsychotics. It included semi-structured interviews at 6 weeks (n = 70) and 6 months (n = 47) after initiating treatment. Narratives regarding change in QoL attributed to xanomeline/trospium and medication satisfaction were coded and categorized. Study Results: Before starting xanomeline/trospium, most participants reported QoL challenges across the following domains: physical (95.7%), social (85.7%), and role (80.0%) functioning, and emotional well-being (74.3%). For the two most common issues in each domain, the percentage of participants who improved by 6 weeks ranged from 44.8% to 83.3%, increasing to 68.0% to 95.2% by 6 months after xanomeline/trospium initiation. Few participants worsened in any of these domains. Participants rated their satisfaction with xanomeline/trospium highly (mean = 8.1 out of 10 at both assessments) and 93.2% would recommend it to a friend. Discussion: Xanomeline/trospium treatment was associated with meaningful improvements across QoL domains that participants had previously identified as challenging, and most participants reported high satisfaction with the medication. These findings should be interpreted cautiously given the open-label design, absence of a comparator group, and potential selection and attrition biases. Within these constraints, the results provide exploratory, participant-centered insights into treatment experience and suggest that muscarinic agonists may influence both symptomatic and functional aspects of schizophrenia, warranting further controlled investigation.


  • Open Access

    A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 1: Perceived Impact on Symptoms

    by William P Horan, Cory Saucier, Peter J Weiden, Amy Claxton, Stephen R Marder, April M Foster, Colin Sauder, Kaitlin LaGasse, Sloan Rucker, Kristi Jackson, et al.

    Introduction: Xanomeline and trospium chloride (formerly KarXT) is a muscarinic M1 and M4 receptor agonist recently approved for the treatment of schizophrenia in adults. Unlike all previously approved antipsychotics, it does not directly block dopamine D2 receptors. Given its novel mechanism of action, understanding patients’ subjective treatment experiences, including perceived symptom changes, is clinically important. Methods: This is a qualitative study embedded within a larger 52-week open-label long-term safety study that investigated patient perspectives on xanomeline/trospium monotherapy in clinically stable outpatients transitioned from previous antipsychotic treatments. A subsample completed up to 2 semi-structured interviews to explore their experience—favorable or unfavorable—approximately 6 weeks (n = 70) and 6 months (n = 47) post-initiation. Thematic analysis was applied to interview transcripts. Results: At study entry, most participants reported symptoms despite ongoing antipsychotic treatment, including positive (auditory hallucinations, >80%), negative (low motivation, >70%), and cognitive (trouble concentrating, >70%) symptoms. Over 60% reported meaningful improvement in one or more symptoms within 6 weeks of starting xanomeline/trospium, increasing to about 80% by 6 months. Less than 10% reported symptom worsening at either time point. Participants described these improvements as personally meaningful, with notable benefits in daily functioning. Discussion: Participants entered this study with various persistent, burdensome schizophrenia symptoms despite ongoing treatment. Most experienced substantial and sustained symptom relief for up to 6 months after initiating xanomeline/trospium treatment. These qualitative findings highlight xanomeline/trospium’s potential to provide meaningful relief across multiple symptom domains and support functional recovery. A companion report explores quality of life and medication satisfaction.


  • Open Access

    Response to Commentaries

    by William P Horan, Amir Kalali, Stephen K Brannan, Wayne Drevets, Atul Mahableshwarkar, Srinivas Rao, Corey Reuteman-Fowler, Adam Savitz, Jaskaran Singh, Gary Walker, et al.


  • Motivational and cognitive correlates of community integration in homeless veterans entering a permanent supported housing program.

    by William P. Horan, Jonathan K. Wynn, Sonya Gabrielian, Shirley M. Glynn, Gerhard S. Hellemann, Robert S. Kern, Junghee Lee, Stephen R. Marder, Catherine A. Sugar, Michael F. Green

    Homelessness is a major public health problem, and serious mental illness (SMI) is highly prevalent in the homeless population. Although supported housing services-which provide permanent housing in the community along with case management-improve housing outcomes, community integration typically remains poor, and little is known about the underlying determinants of poor community integration postresidential placement. The general SMI literature has indicated that motivational and cognitive ability factors are key determinants of successful community integration, which provides a foundation for examining this issue. This study evaluated whether interview- and performance-based assessments of motivation, nonsocial and social-cognitive ability, and psychiatric symptoms were associated with community integration indices in 2 samples of homeless veterans either with (N = 96) or without (N = 80) a psychotic disorder who had recently been admitted to a supported housing program but who had not yet attained housing. Motivation indices, including experiential negative symptoms and defeatist performance attitudes, stood out as the most robust correlates (rs = -.30 to -.69) of community integration across both samples, particularly for social role participation. Demographics, general psychiatric symptoms, and nonsocial cognition showed generally weak relations with community integration, though social cognition showed a few relations. The consistent findings across samples point to the importance of motivational factors for understanding the determinants of poor community integration in this complex population. Further, interventions that target motivational challenges may have widespread usefulness for enhancing community integration outcomes beyond obtaining housing. (PsycINFO Database Record (c) 2020 APA, all rights reserved).


  • Social Cognitive Skills Training for Psychosis With Community-Based Training Exercises: A Randomized Controlled Trial

    by William P Horan, Michelle Dolinsky, Junghee Lee, Robert S Kern, Gerhard Hellemann, Catherine A Sugar, Shirley M Glynn, Michael F Green

    Impairments in social cognition are key determinants of poor functioning in psychosis and an important new target for treatment development. Initial studies support the feasibility and efficacy of training interventions for social cognition, but have been small and have had substantial methodological limitations. This report describes the largest rigorously controlled study of a social cognitive treatment to date. We evaluated the efficacy of a refined version of the 24-session Social Cognitive Skills Training (SCST) program, and whether adding in vivo training sessions in community settings would enhance generalization to functional improvements. One hundred thirty-nine outpatients with psychotic disorders were randomly assigned to one of 3 time- and format-matched conditions: (1) SCST plus in vivo community-based training, (2) SCST plus clinic-based training, or (3) Illness management control condition. SCST targeted the domains of emotion processing, social perception, attributional bias, empathy, and mentalizing. Assessments of social cognition, nonsocial cognition, symptoms, and functioning were completed at baseline, mid-treatment, posttreatment, and 3-month follow-up. On the primary social cognitive outcome measures, there was significant, durable SCST-related improvement in facial emotion identification. There was also a significant SCST benefit for emotional intelligence and an in vivo training effect for empathy, though these improvements were not durable. Further, there were no overall or in vivo-related changes in functioning. This study bolsters and extends support for the efficacy of SCST in a relatively large and rigorously controlled trial, although our effort to enhance generalization to functional improvements through in vivo community-based training was not successful.


  • Altered experiential, but not hypothetical, delay discounting in schizophrenia.

    by William P. Horan, Matthew W. Johnson, Michael F. Green

    Delay discounting (DD) is a future-oriented decision-making process that refers to whether one is willing to forego a smaller, sooner reward for the sake of a larger, later reward. It can be assessed using hypothetical tasks, which involve choices between hypothetical rewards of varying amounts over delay periods of days to years, or experiential tasks, which involve receiving actual rewards in real time over delay periods of seconds to minutes. Initial studies in schizophrenia have only used hypothetical tasks and have been mixed in finding either elevated or normal levels of DD. One hundred thirty-one outpatients with schizophrenia and 70 healthy controls completed hypothetical and experiential DD tasks involving monetary rewards, and the schizophrenia group was retested after 4 weeks. Although both groups showed qualitatively similar hyperbolic discounting functions on both tasks, they showed a quantitative DD difference. The schizophrenia showed higher DD than controls on the experiential task but normal DD on the hypothetical task. This pattern was not attributable to a range of potential confounds, including smoking status, substance use disorder status, or neurocognition. It was also not attributable to differences in the test-retest reliability, which was good for both tasks. The schizophrenia group's robust pattern of altered experiential but normal hypothetical task performance points to key factors that may contribute to impaired DD in this disorder. These may include increased valuation of small (but not large) monetary rewards, or a hypersensitivity to costs associated with waiting inactively for those rewards. (PsycINFO Database Record


  • Open Access

    Distinct patterns of dysfunctional appetitive and aversive motivation in bipolar disorder versus schizophrenia: An event-related potential study.

    by William P. Horan, Jonathan K. Wynn, Greg Hajcak, Lori Altshuler, Michael F. Green

    Schizophrenia and bipolar disorder are associated with different clinical profiles of disturbances in motivation, yet few studies have compared the neurophysiological correlates of such disturbances. Outpatients with schizophrenia (n = 34), or bipolar disorder I (n = 33), and healthy controls (n = 31) completed a task in which the late positive potential (LPP), an index of motivated attention, was assessed along motivational gradients determined by apparent distance from potential rewards or punishments. Sequences of cues signaling possible monetary gains or losses appeared to loom progressively closer to the viewer; a reaction time (RT) task after the final cue determined the outcome. Controls showed the expected pattern with LPPs for appetitive and aversive cues that were initially elevated, smaller during intermediate positions, and escalated just prior to the RT task. The clinical groups showed different patterns in the final positions just prior to the RT task: the bipolar group's LPPs to both types of cues peaked relatively early during looming sequences and subsequently decreased, whereas the schizophrenia group showed relatively small LPP escalations, particularly for aversive cues. These distinct patterns suggest that the temporal unfolding of attentional resource allocation for motivationally significant events may qualitatively differ between these disorders. (PsycINFO Database Record


  • Open Access

    Pain empathy in schizophrenia: an fMRI study

    by William P. Horan, Amy M. Jimenez, Junghee Lee, Jonathan K. Wynn, Naomi I. Eisenberger, Michael F. Green

    Although it has been proposed that schizophrenia is characterized by impaired empathy, several recent studies found intact neural responses on tasks measuring the affective subdomain of empathy. This study further examined affective empathy in 21 schizophrenia outpatients and 21 healthy controls using a validated pain empathy paradigm with two components: (i) observing videos of people described as medical patients who were receiving a painful sound stimulation treatment; (ii) listening to the painful sounds (to create regions of interest). The observing videos component incorporated experimental manipulations of perspective taking (instructions to imagine ‘Self’ vs ‘Other’ experiencing pain) and cognitive appraisal (information about whether treatment was ‘Effective’ vs ‘Not Effective’). When considering activation across experimental conditions, both groups showed similar dorsal anterior cingulate cortex (dACC) and anterior insula (AI) activation while merely observing others in pain. However, there were group differences associated with perspective taking: controls showed relatively greater dACC and AI activation for the Self vs Other contrast whereas patients showed relatively greater activation in these and additional regions for the Other vs Self contrast. Although patients demonstrated grossly intact neural activity while observing others in pain, they showed more subtle abnormalities when required to toggle between imagining themselves vs others experiencing pain.


  • The interactive effects of negative symptoms and social role functioning on suicide ideation in individuals with schizophrenia

    by Danielle R. Jahn, Melanie E. Bennett, Stephanie G. Park, Raquel E. Gur, William P. Horan, Ann M. Kring, Jack J. Blanchard